Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 19Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Non-Hodgkin 8Neoplasms 7Lymphoma 7Recurrence 5Lymphoma, B-Cell 5Multiple Myeloma 4Burkitt Lymphoma 4Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Prolymphocytic, B-Cell 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1

Interventions

ibrutinib 1fludarabine phosphate 1Whole-Body Irradiation 1Tacrolimus 1Standard of Care 1Rituximab 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Aplastic × ibrutinib × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡